{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:08:29Z","timestamp":1790960909722,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bispecific antibodies (BsAb) approved for relapsed\/refractory B-cell non-Hodgkin lymphomas (R\/R NHL) redirect T-cells to malignant cells and have been associated with cardiovascular adverse events (CVAEs). We analyzed the FDA Adverse Event Reporting System (FAERS) data from December 2022 to September 2025 to characterize the safety of mosunetuzumab, glofitamab, and epcoritamab. Among 246,490 adverse event reports, 1,931 involved BsAbs. CVAEs occurred in 336 (17.4%) BsAb-associated reports of which 132 (39.3%) were fatal. The most frequent CVAEs were shock (3.2%), bleeding (3.0%), and hypotension (2.7%). As a class, BsAbs were associated with increased reporting of hypotension (aROR: 2.15, 95% CI\u2009=\u20091.48\u20133.13) and fatal CVAEs (aROR: 2.04, 95% CI\u2009=\u20091.60\u20132.60) compared to all other drugs in the FAERS database. Individual drugs showed distinct patterns: epcoritamab showed the strongest hypotension signal (aROR: 2.37, 95% CI\u2009=\u20091.55\u20133.62) and increased fatal CVAE reporting (aROR: 2.26, 95% CI\u2009=\u20091.72\u20132.98), while mosunetuzumab was associated with atrial fibrillation\/flutter (aROR: 3.04, 95% CI\u2009=\u20091.53\u20136.03), supraventricular tachycardia (aROR: 2.72, 95% CI\u2009=\u20091.42\u20135.21), and tachyarrhythmias (aROR: 2.60, 95% CI\u2009=\u20091.44\u20134.72). CVAEs occurred earlier than non-CVAEs (median, 10 vs. 16 days,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Cytokine release syndrome occurred in 33.4% of BsAb-related adverse events, with hypotension most commonly overlapping (53.8%), while most arrhythmias occurred independently. These findings highlight cardiovascular toxicity signals associated with BsAbs and underscore the need for continued surveillance, risk stratification, and targeted cardiovascular assessment as these expand into broader clinical practice. However, consistent with the limitations of pharmacovigilance analyses, particularly the reliance on spontaneous adverse event reporting, these observations require confirmation in prospective studies.\n                  <\/jats:p>","DOI":"10.1186\/s13045-026-01809-3","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:17:16Z","timestamp":1779790636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas"],"prefix":"10.1186","volume":"19","author":[{"given":"Malak","family":"Munir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"1809_CR1","unstructured":"National Comprehensive Cancer Network. B-Cell Lymphomas. (Version 2.2026). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (accessed 5 Mar2026)."},{"key":"1809_CR2","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","volume":"129","author":"A Asnani","year":"2021","unstructured":"Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, et al. Preclinical Models of Cancer Therapy\u2013Associated Cardiovascular Toxicity. Circ Res. 2021;129:e21\u201334.","journal-title":"Circ Res"},{"key":"1809_CR3","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2013.55.0459","volume":"32","author":"MK Accordino","year":"2014","unstructured":"Accordino MK, Neugut AI, Hershman DL. Cardiac Effects of Anticancer Therapy in the Elderly. J Clin Oncol. 2014;32:2654\u201361.","journal-title":"J Clin Oncol"},{"key":"1809_CR4","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","volume":"8","author":"M Munir","year":"2024","unstructured":"Munir M, Sayed A, Addison D, Epperla N. Cardiovascular toxicities associated with novel cellular immune therapies. Blood Adv. 2024;8:6282\u201396.","journal-title":"Blood Adv"},{"key":"1809_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse Cardiovascular and Pulmonary Events Associated with Chimeric Antigen Receptor T-cell Therapy. J Am Coll Cardiol. 2021;78:1800\u201313.","journal-title":"J Am Coll Cardiol"},{"key":"1809_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008518","author":"A Sayed","year":"2024","unstructured":"Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, et al. Cardiovascular Toxicities Associated with Bi-specific T-cell Engager Therapies. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008518.","journal-title":"J Immunother Cancer"},{"key":"1809_CR7","doi-asserted-by":"publisher","unstructured":"Tai D, Sandhu N, Dermarderosian A, Mkrtchyan N, Park D, Akhtari M. Meta-analysis of the cardiovascular adverse effects of bispecific antibodies in malignant hematology therapies. J Clin Oncol. 2025;43. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e14503.","DOI":"10.1200\/JCO.2025.43.16_suppl.e14503"},{"key":"1809_CR8","doi-asserted-by":"publisher","first-page":"e19013","DOI":"10.1200\/JCO.2024.42.16_suppl.e19013","volume":"42","author":"S Jumean","year":"2024","unstructured":"Jumean S, Elemian S, Aiman W, Ali MA, Ramahi A, Al Omour B, et al. Efficacy and safety of mosunetuzumab-based regimens as first-line therapy in non-Hodgkin lymphomas: A systematic review of clinical trials. J Clin Oncol. 2024;42:e19013\u201319013.","journal-title":"J Clin Oncol"},{"key":"1809_CR9","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1200\/JCO.2023.41.16_suppl.7519","volume":"41","author":"L Falchi","year":"2023","unstructured":"Falchi L, Clausen M, Offner F, De Vos S, Brody J, Linton KM, et al. Metabolic response rates of epcoritamab\u2009+\u2009R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit\/triple-hit lymphoma: Updated EPCORE NHL-2 data. J Clin Oncol. 2023;41:7519\u20137519.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01809-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:17:17Z","timestamp":1779790637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01809-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01809-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}